Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients With Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia

Leuk Lymphoma. 2002 Jan;43(1):149-51. doi: 10.1080/10428190210178.

Abstract

Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment.

MeSH terms

  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal / toxicity
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / metabolism*
  • Antineoplastic Agents / standards
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents / toxicity
  • Biomarkers / analysis
  • Disease-Free Survival
  • Drug Evaluation
  • Flow Cytometry
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukemia, Prolymphocytic / diagnosis
  • Leukemia, Prolymphocytic / drug therapy
  • Leukemia, Prolymphocytic / mortality
  • Male
  • Middle Aged
  • Rituximab
  • Salvage Therapy
  • Survival Rate
  • Therapeutic Equivalency
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Biomarkers
  • Rituximab